-
CDH1–TK1 Pathway in Chemoresistant AML
2026-10-08
A 2026 study identifies a CDH1–TK1–dependent nucleotide salvage program that helps acute myeloid leukemia cells tolerate replication stress and resist chemotherapy. Its integrated transcriptomic, mechanistic, and xenograft evidence positions TK1 as a candidate biomarker for replication-stress-targeted treatment, while leaving important questions about clinical validation and combination therapy safety.
-
1-methyl Adenosine: Evidence, Uses, and Limits
2026-10-07
1-methyl Adenosine, also called 1-methyl Ado or m1A, is a modified purine ribonucleoside associated with RNA turnover and purine metabolism. Peer-reviewed evidence supports sensitive cellular quantification, while mechanistic, clinical biomarker, and therapeutic claims require additional validation.
-
HotStart Universal 2X Green qPCR Master Mix for ER Stress
2026-10-07
Explore how HotStart Universal 2X Green qPCR Master Mix can support gene expression quantification in studies of endoplasmic reticulum stress and intestinal stem-cell biology. This article focuses on evidence interpretation, assay specificity, and how qPCR fits within a broader mechanistic framework.
-
Toremifene in Prostate Cancer Research: Evidence & Limits
2026-10-06
This source-grounded overview examines Toremifene as a selective estrogen-receptor modulator in hormone-responsive cancer research and compares supplier-reported cell-growth findings with published evidence on the TSPAN18–STIM1 axis in prostate cancer bone metastasis. It distinguishes established observations from hypotheses and explains why the available evidence does not demonstrate that Toremifene targets TSPAN18, STIM1, or metastatic disease.
-
WAY-100635: 5-HT1A Receptor Antagonist
2026-10-05
WAY-100635 is a selective, silent serotonin 5-HT1A receptor antagonist used to interpret receptor-binding, functional, behavioral, and imaging research. Available evidence supports strong antagonist activity, but it does not establish clinical efficacy, diagnostic approval, or a direct role in cannabidiol-mediated pain effects.
-
PreScission Protease: Evidence, Scope, and Limits
2026-10-05
A source-grounded overview of PreScission Protease and HRV 3C protease, using the supplied Drosophila Keap1 study to clarify mechanism, evidence quality, interpretation, applicability, and key limitations.
-
Nanaomycin A and the Epigenetic Logic of NEPC
2026-10-04
Neuroendocrine prostate cancer can emerge as a therapy-induced state marked by lineage plasticity, stemness, and treatment resistance. The supplied study positions DNMT3B as a mechanistic driver and Nanaomycin A as a pharmacologic probe, while also defining the evidence gaps translational teams must address before clinical positioning.
-
ONX-0914 and Airway Type 2 Inflammation
2026-10-03
A source-grounded overview of ONX-0914 (PR-957) and immunoproteasome biology, emphasizing recent evidence linking LMP7 activity to IL-4Rα turnover, eosinophilic inflammation, and airway hyperresponsiveness, while distinguishing experimental findings from supplier claims and identifying key translational limitations.
-
Hexamethonium Bromide in Autonomic Research
2026-10-02
Hexamethonium Bromide converts a broad ganglionic-blockade concept into a practical tool for separating sympathetic contributions from blood-pressure phenotypes. This guide connects telemetry, angiotensin II hypertension, sex-specific analysis, solution handling, and troubleshooting for reproducible autonomic experiments.
-
Gallein Workflows for GPCR Signaling Research
2026-10-01
Gallein provides a practical way to test whether G protein βγ signaling contributes to GPCR-driven phenotypes in metabolism, cancer, immunity, and cardiac disease models. This workflow-focused guide connects the lactate-GPR81/FARP1 discovery to assay design, controls, formulation, and troubleshooting without overstating what the compound proves.
-
EDC.HCl Coupling Workflow Guide
2026-10-01
EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation with primary amines in peptide synthesis and bioconjugation. It is intended for controlled in vitro workflows; the available dossier reports no in vivo or clinical data and advises against long-term storage of solutions.
-
Cy5 Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-30
A scenario-based guide to using Cy5 Goat Anti-Mouse IgG (H+L) Antibody, SKU K1210, for reproducible mouse IgG detection alongside viability, proliferation, and cytotoxicity assays. It covers compatibility, signal interpretation, storage, optimization, and practical vendor-selection criteria.
-
Salvianolic Acid B and the Logic of Fibrotic ECM
2026-09-30
A mechanistic guide to using Salvianolic acid B as an LH2-directed research compound for collagen cross-linking, extracellular matrix remodeling, and pulmonary fibrosis studies.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-29
The reference study identifies nitric oxide signaling as a mechanistic contributor to puerarin-induced osteogenic differentiation in rat dental follicle cells. Its pharmacological inhibition experiment links NO production with ALP activity, osteogenic marker expression, and the sGC–cGMP–PKG-1 axis, while also defining important limits for interpretation and translation.
-
JZL184: From 2-AG Biology to TBI Translation
2026-09-29
JZL184 offers a mechanistically precise way to increase endogenous 2-AG and interrogate MAGL–CB1 biology. This article connects endocannabinoid signaling to GLT-1 regulation after traumatic brain injury, outlines validation workflows, and identifies the controls needed for translational interpretation.